In addition, it has been shown that transdermal E2 in contrast to the oral CEE does not increase CRP levels in healthy women, further supporting the notion that transdermal E2 and oral CEE exert different effects on CHD risk factors. This evidence concerns the gene CRP and coronary artery disorder.